万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://clinicalepigeneticsjournal.biomedcentral.com/
https://link.springer.com/journal/13148/volumes-and-issues
3、投稿网址：https://www.editorialmanager.com/clep
4、期刊刊期：年刊，一年出版1期。
2022年1月18日星期二
投稿须知【官网信息】
Clinical Epigenetics
Submission guidelines
Our 3-step submission process
Before you submit
Now you’ve identified a journal to submit to, there are a few things you should be familiar with before you submit.
Make sure you are submitting to the most suitable journal - Aims and scope
Understand the costs and funding options - Fees and funding
Make sure your manuscript is accurate and readable - Language editing services
Understand the copyright agreement - Copyright
Ready to submit
To give your manuscript the best chance of publication, follow these policies and formatting guidelines.
General formatting rules for all article types - Preparing your manuscript
Make sure your submission is complete - Prepare supporting information
Copyright and license agreement - Conditions of publication
Read and agree to our Editorial Policies - Editorial policies
Submit and promote
After acceptance, we provide support so your article gains maximum impact in the scientific community and beyond.
Please note that manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.
Who decides whether my work will be accepted? - Peer-review policy
Want to submit to a different journal? - Manuscript transfers
Spreading the word - Promoting your publication
Submit manuscript
Aims and scope
Encompassing the broad spectrum of epigenetics research from basic research to innovations in therapeutic treatments, Clinical Epigenetics is a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment. The journal particularly welcomes submissions involving clinical trials, translational research, new and innovative methodologies and model organisms providing mechanistic insights. The journal is divided into the following sections:
Aging and development epigenetics
Allergy, immunology, and pathogen epigenetics
Cancer epigenetics and diagnostics
Cardiovascular epigenetics
Endocrinology and metabolic epigenetics
Environmental epigenetics
Epigenetic biomarkers
Epigenetic technologies
Epigenetic Drugs, Trials and Therapy
Innovative therapies
Lifestyle epigenetics
Neurology and psychiatry epigenetics
Regenerative medicine
Reproductive and transgenerational epigenetics
For more information on the the section aims and scope visit our section information page. If you are unclear which section would be best suited to your submission, we invite you to submit a pre-submission inquiry by selecting the Contact Us option here.
Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications
Manuscripts focusing on differential RNA expression levels (coding or non-coding) or on RNA modifications cannot be considered for publication in Clinical Epigenetics since these aspects are not part of epigenetics per se.
In general, non-coding RNAs affect their target genes at the RNA level, which classifies these molecules as post-transcriptional gene expression regulators. The chromatin effects induced by some ncRNA do not yet justify this, to be included as a general mechanism of action of non-coding RNAs. Similarly, although modifications of RNA molecules resemble modifications of DNA or histone proteins, so do post-translational modifications of non-chromatin proteins. As such, RNA modifications are a novel class of markers, but they are not different from general posttranslational protein modifications (which also are not considered part of epigenetics).
For manuscripts on non-coding RNAs or RNA modifications to be considered for publication in Clinical Epigenetics, the authors must provide at least one of the following:
data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes); or
insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA; or
insights in mitotic stability of the RNA-induced effect.
Editorial Policy Regarding Submissions Focusing on In silico research
Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Clinical Epigenetics, unless the manuscript presents:
new insights with well-described strong clinical impact and/or
additional insights into biological mechanisms (“wet-lab” validations) and/or
validations of findings in a replication cohort.
Fees and funding
Article-processing charges
Open access publishing is not without costs. Clinical Epigenetics therefore levies an article-processing charge of £2190.00/$3090.00/€2590.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.
Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.
For more information on APCs please see our Journal Pricing FAQs
……
更多详情：
https://clinicalepigeneticsjournal.biomedcentral.com/submission-guidelines
